Menu IR Home IR Home News Releases Events and Presentations Stock Information Stock Quote Interactive Stock Chart Key Ratios Analyst Coverage FAQs Financials and SEC Filings Annual Reports and Proxies Quarterly Financial Reports SEC Filings Corporate Governance Documents and Charters Management Board of Directors Committee Composition Contact the Board Contact Us News Releases Investor Alerts Year All Years 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Jun 22, 2020 Immunic, Inc. to Join Russell 3000® Index Jun 15, 2020 Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 Jun 10, 2020 Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock Jun 9, 2020 Immunic, Inc. Announces Proposed Public Offering of Common Stock Jun 9, 2020 Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 May 29, 2020 Immunic, Inc. to Participate in Investor and Industry Conferences in June May 19, 2020 Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020 - Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 - May 13, 2020 Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients May 8, 2020 Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity Apr 23, 2020 Immunic, Inc. Announces Pricing of $15 Million Financing Show 5102550100 per page«123456»
